The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy
It is destroyed by an enzyme called DPP-4 almost as fast as the body makes it
Using smaller doses lowers these problems and makes the medication easier on the body
They also underscore a strategic imperative: manufacturers must urgently expand capacity to capitalize on the market opportunity, while dealing with supply constraints and time-to-market
The safest patient-friendly answer is: possibly, in selected patientsespecially those with existing diabetic retinopathy, especially early after starting treatment, and especially when glucose improves rapidly
Before treatment, she experienced multi-week flares that significantly impacted quality of life